Cadre Reports Q3 2026 Net Sales of $202.9M; Limited Details Provided

What happened

Cadre Holdings reported third quarter 2026 net sales of $202.9 million, bringing nine-month sales to $565.4 million, nearly matching the full-year 2024 total of $567.6 million and suggesting robust top-line expansion. The release lacks profitability, backlog, or segment breakdown, making it impossible to assess whether growth is translating into improved margins or free cash flow. Compared to prior periods, Q3 2026 revenue appears higher than the $157.1 million reported in Q2 2025, though year-over-year comparisons are not provided. The company trades at a premium valuation of 44x P/E and 17.5x EV/EBITDA, leaving little room for disappointment. Investors need more granular financials to evaluate whether execution on key programs is on track.

Implication

The revenue print is encouraging but incomplete; maintain HOLD until full financials confirm margin expansion and backlog conversion. The nine-month sales nearly equal prior year's total, indicating healthy demand, but without gross margin and backlog numbers, we cannot validate that growth is profitable. Given the valuation premium, investors should require evidence of FCF improvement or program milestones before adding positions. Key watch items remain LSAPI ramp, Next Gen Bomb Suit fielding, and supply chain cost pressures. A sustained revenue beat with expanding margins could warrant an upgrade, while any margin compression or FCF deterioration would justify a downgrade.

Thesis delta

No material thesis change. The Q3 2026 net sales figure is consistent with ongoing demand but provides no new information on profitability or backlog. The HOLD rating remains based on full valuation and unproven FCF conversion; we require more granular metrics to adjust.